ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
줄기세포 항체 시장 규모는 최근 급속히 확대되고 있습니다. 2024년 20억 4,000만 달러로 평가되었고, 2025년에는 23억 2,000만 달러에 달할 것으로 추정되며, CAGR 13.7%로 성장이 전망되고 있습니다. 지난 수년간의 성장은 줄기세포 연구에 대한 투자 증가, 줄기세포 기반 치료법의 보급 확대, 바이오마커 확인에 사용되는 항체에 대한 수요 증가, 재생 의료에 대한 자금 증가, 줄기세포 분석을 위한 고처리량 스크리닝 및 유동 세포 측정 기술의 확대와 연관되어 왔습니다.
줄기세포 항체 시장 규모는 향후 수년간 급속한 성장이 예상되고 있습니다. 2029년에는 38억 2,000만 달러에 달할 것으로 예측되며, CAGR 13.3%로 성장할 전망입니다. 예측 기간에 있어서 성장 요인으로는 전문적인 줄기세포 항체의 사용 증가, 신흥 지역에 있어서의 연구 인프라 확충, 줄기 세포 연구에 있어서의 학술 기관 및 산업계의 제휴 강화, 만성 및 변성 질환 증가에 수반하는 줄기세포 연구 수요 증가, 맞춤형 의료 및 세포 기반 어세이 개발의 진전 등을 들 수 있습니다. 예측 기간 동안 예상되는 주요 동향으로는 재조합 항체 및 설계 항체 기술의 진전, 고처리량 항체 스크리닝 및 자동화 혁신, 정밀한 줄기세포 마커 식별 및 분화 분석의 진보, 항체 설계 및 검증에서 AI와 머신러닝의 통합, 줄기세포 서브 집단과 틈새 환경을 표적으로 하는 신규 항체의 창출을 들 수 있습니다.
향후 수년간 만성 질환 증가가 줄기세포 항체 시장의 성장을 이끌 것으로 예측됩니다. 만성 질환은 천천히 진행되고 장기간 지속되기 때문에 종종 장기적인 의료 치료가 필요합니다. 이러한 질병 증가는 주로 앉기 쉬운 생활 방식과 운동 부족으로 인해 심장 질환, 당뇨병 및 기타 대사성 질환과 같은 위험을 증가시킵니다. 줄기세포 항체는 연구개발의 진전에 필수적인 줄기세포의 정밀한 동정과 분리를 가능하게 함으로써 만성질환 관리에 중요한 역할을 합니다. 이러한 항체는 줄기세포의 거동을 표적화하고 조절하는 데 도움이 되며, 재생 의료 및 개인화 치료의 효과를 향상시킵니다. 예를 들어 2024년 6월 영국 국민보건서비스(NHS)가 발표한 데이터에 따르면 2023년 비당뇨병성 고혈당 및 당뇨병전증으로 진단받은 환자수는 361만 5,330명에 달했으며, 전년 대비 18% 증가를 보였습니다. 이러한 유병률의 상승에 따라 줄기세포 기반 치료법에 의한 만성질환 관리의 진전을 통해 줄기세포 항체는 시장 성장을 견인하는 중요한 역할을 담당하고 있습니다.
개인화된 의료에 대한 수요 증가도 줄기세포 항체 시장의 성장을 가속할 것으로 예측됩니다. 맞춤형 의료는 유전적 요인, 환경 요인, 생활 습관에 따라 개별 환자에게 치료법을 조정하고 치료 효과를 최적화하는 것입니다. 유전체 기술의 진보로 유전적 변이의 정밀한 동정이 가능해지고, 맞춤형 치료법의 개발이 진전됨으로써, 맞춤형 치료에 대한 수요가 높아지고 있습니다. 줄기세포 항체는 특정 줄기세포 집단을 정확하게 식별하고 표적화할 수 있기 때문에 맞춤형 의료에서 매우 중요합니다. 줄기세포를 정밀하게 분리 및 조작하는 이 능력은 맞춤형 치료법이나 진단법의 개발을 촉진해, 치료의 정밀도 및 치료 효과를 향상시킵니다. 예를 들어, 2024년 2월에 개인화된 메디신 연합(PMC)이 발표한 바에 따르면, 미국 식품의약국(FDA)은 2023년에 26건의 새로운 맞춤형 의료를 승인했습니다. 이것은 2022년 12건에서 크게 증가한 수치입니다. 개인화된 의료의 이러한 성장은 재생 의학 및 질병 특이적 치료의 진전에 필수적인 줄기세포 항체에 대한 수요를 더욱 증가시키고 있습니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향 및 전략
제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁 및 관세, 그리고 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석 및 전략 분석 프레임워크
세계의 줄기세포 항체 : PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인 및 억제요인)
최종 이용 산업의 분석
세계의 줄기세포 항체 시장 : 성장률 분석
세계의 줄기세포 항체 시장 실적 : 규모 및 성장(2019-2024년)
세계의 줄기세포 항체 시장 예측 : 규모 및 성장(2024-2029년, 2034년)
세계의 줄기세포 항체 : 총 잠재 시장 규모(TAM)
제6장 시장 세분화
세계의 줄기세포 항체 시장 : 항체 유형별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
단일클론 항체
폴리클로날 항체
재조합 항체
이중특이적 항체
세계의 줄기세포 항체 시장 : 제품 제제별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
액제 제제
동결건조 제제
항체 접합체
비결합형 항체
세계의 줄기세포 항체 시장 : 용도별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
연구
임상 진단
치료 용도
단백질 정제
세계의 줄기세포 항체 시장 : 최종 사용자별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
학술기관
제약기업
바이오테크놀러지 기업
병원 및 진단실험실
세계의 줄기세포 항체 시장 : 단일클론 항체 유형별 세분화 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
인간화 단일클론 항체
키메라 단일클론 항체
마우스 단일클론 항체
완전 인간 단일클론 항체
세계의 줄기세포 항체 시장 : 폴리클로날 항체 유형별 세분화 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
동물 유래 폴리클로날 항체
재조합 폴리클로날 항체
친화성 정제 폴리클로날 항체
2차 폴리클로날 항체
세계의 줄기세포 항체 시장 : 재조합 항체 유형별 세분화 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
싱글 체인 가변 영역 항체
단편 항원 결합 항체
나노 바디
키메라형 재조합 항체
세계의 줄기세포 항체 시장 : 이중 특이성 항체 유형별 세분화 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
T세포 인게이지형 이중 특이성 항체
이중 표적 이중 특이성 항체
면역 체크포인트 이중 특이성 항체
종양 관련 이중 특이성 항체
제7장 지역별 및 국가별 분석
세계의 줄기세포 항체 시장 : 지역별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
세계의 줄기세포 항체 시장 : 국가별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도 및 기업 프로파일
줄기세포 항체 시장 : 경쟁 구도
줄기세포 항체 시장 : 기업 프로파일
Thermo Fisher Scientific Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
Bio-Rad Laboratories Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
Bio-Techne Corp. : 개요, 제품 및 서비스, 전략 및 재무 분석
Miltenyi Biotec : 개요, 제품 및 서비스, 전략 및 재무 분석
Cell Signaling Technology Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
제31장 기타 주요 기업 및 혁신 기업
OriGene Technologies Inc.
Enzo Biochem
GeneTex Inc.
Proteintech Group Inc.
Rockland Immunochemicals Inc.
Bioss Inc.
ReproCELL
Lucerna-Chem AG
LifeSpan BioSciences
Creative Biogene
MyBioSource Inc.
Imgenex
Ams Biotechnology Ltd.
Cell Biologics Inc.
HUABIO Inc.
제32장 세계 시장 경쟁 벤치마킹 및 대시보드
제33장 주요 인수합병(M&A)
제34장 최근 시장 동향
제35장 시장의 잠재력이 높은 국가, 부문 및 전략
줄기세포 항체 시장(2009년) : 새로운 기회를 제공하는 국가
줄기세포 항체 시장(2009년) : 새로운 기회를 제공하는 부문
줄기세포 항체 시장(2009년) : 성장 전략
시장 동향에 기초한 전략
경쟁 전략
제36장 부록
AJY
영문 목차
영문목차
A stem cell antibody is a laboratory-generated molecule engineered to specifically recognize and attach to proteins or markers found on stem cells. It is used to identify, isolate, or monitor stem cells in both research and therapeutic settings. These antibodies allow scientists to examine stem cell behavior, distinguish different cell types, and develop targeted treatments in regenerative medicine.
The primary antibody types used in stem cell applications include monoclonal antibodies, polyclonal antibodies, recombinant antibodies, and bispecific antibodies. Monoclonal antibodies (mAbs) are laboratory-produced molecules that bind selectively to a single target on cells or pathogens and are primarily used for diagnosing and treating diseases. They are available in various product formats, such as liquid preparations, lyophilized forms, conjugated antibodies, and unconjugated antibodies. Their applications span research, clinical diagnostics, therapeutic use, and protein purification, supporting end users such as academic institutions, pharmaceutical companies, biotechnology organizations, and hospitals and diagnostic laboratories.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the healthcare sector, particularly in the supply of critical medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are facing higher costs for imported surgical instruments, imaging equipment, and consumables such as syringes and catheters, many of which have limited domestic alternatives. These increased costs are straining healthcare budgets, leading some providers to delay equipment upgrades or pass on expenses to patients. Additionally, tariffs on raw materials and components are disrupting the production of essential drugs and devices, causing supply chain bottlenecks. In response, the industry is diversifying sourcing strategies, boosting local manufacturing where possible, and advocating for tariff exemptions on life-saving medical products.
The stem cell antibody market research report is one of a series of new reports from The Business Research Company that provides stem cell antibody market statistics, including stem cell antibody industry global market size, regional shares, competitors with a stem cell antibody market share, detailed stem cell antibody market segments, market trends and opportunities, and any further data you may need to thrive in the stem cell antibody industry. This stem cell antibody market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The stem cell antibody market size has grown rapidly in recent years. It will grow from $2.04 billion in 2024 to $2.32 billion in 2025 at a compound annual growth rate (CAGR) of 13.7%. Growth during the historic period can be linked to increasing investments in stem cell research, the widening use of stem cell-based therapies, rising demand for antibodies used in biomarker identification, greater funding for regenerative medicine, and the expansion of high-throughput screening and flow cytometry techniques for stem cell analysis.
The stem cell antibody market size is expected to see rapid growth in the next few years. It will grow to $3.82 billion in 2029 at a compound annual growth rate (CAGR) of 13.3%. Growth in the forecast period can be attributed to the rising use of specialized stem cell antibodies, expanding research infrastructure in emerging regions, increasing collaboration between academic and industry partners in stem cell research, the growing prevalence of chronic and degenerative diseases driving demand for stem cell studies, and the advancement of personalized medicine and cell-based assay development. Key trends expected in the forecast period include progress in recombinant and engineered antibody technologies, innovations in high-throughput antibody screening and automation, advancements in precise stem cell marker identification and differentiation assays, the integration of AI and machine learning in antibody design and validation, and the creation of novel antibodies targeting stem cell sub-populations and niche environments.
The rising prevalence of chronic diseases is expected to drive the growth of the stem cell antibody market in the coming years. Chronic diseases, which develop slowly and persist over time, often require long-term medical care. The increasing prevalence of these diseases is largely due to sedentary lifestyles and minimal physical activity, which raise the risk of conditions such as heart disease, diabetes, and other metabolic disorders. Stem cell antibodies play a crucial role in managing chronic diseases by enabling the precise identification and isolation of stem cells, which are key to advancing research and therapeutic development. These antibodies help in targeting and modulating stem cell behavior, improving the effectiveness of regenerative medicine and personalized therapies. For example, in June 2024, the National Health Service (NHS) in the UK reported that 3,615,330 individuals were diagnosed with non-diabetic hyperglycemia or pre-diabetes in 2023, marking an 18% increase from the previous year. With this increasing prevalence, stem cell antibodies are playing a key role in driving market growth by advancing chronic disease management through stem cell-based therapies.
The growing demand for personalized medicine is also expected to propel the growth of the stem cell antibody market. Personalized medicine involves tailoring treatments to individual patients based on genetic, environmental, and lifestyle factors, optimizing therapeutic outcomes. The demand for personalized treatments has increased with advancements in genomic technologies, which allow for precise identification of genetic variations and enable the development of customized therapies. Stem cell antibodies are critical in personalized medicine as they allow for the specific identification and targeting of particular stem cell populations. This ability to precisely isolate and manipulate stem cells enhances the development of tailored therapies and diagnostics, improving treatment accuracy and therapeutic efficacy. For instance, in February 2024, the Personalized Medicine Coalition (PMC) noted that the U.S. Food and Drug Administration (FDA) approved 26 new personalized medicines in 2023, a significant increase from the 12 approved in 2022. This rise in personalized medicine is fueling the demand for stem cell antibodies, which are essential for advancing regenerative medicine and disease-specific therapies.
In December 2023, Danaher Corporation, a US-based life sciences company, acquired Abcam plc for approximately $5.7 billion. This acquisition is aimed at strengthening Danaher's life sciences portfolio by integrating Abcam's extensive range of high-quality antibodies and reagents. Abcam, a UK-based biotechnology company, specializes in manufacturing and providing stem cell antibodies for scientific research. With this acquisition, Danaher aims to support research, diagnostics, and therapeutic development across various sectors, including regenerative medicine, where stem cell antibodies play a pivotal role. The acquisition further underscores the growing importance of stem cell antibodies in advancing scientific research and the development of targeted therapies for chronic diseases.
Major companies operating in the stem cell antibody market are Thermo Fisher Scientific Inc., Merck KGaA, Bio-Rad Laboratories Inc., Bio-Techne Corporation, STEMCELL Technologies Inc., Miltenyi Biotec GmbH, Cell Signaling Technology Inc., OriGene Technologies Inc., Enzo Life Sciences Inc., GeneTex Inc., Proteintech Group Inc., Rockland Immunochemicals Inc., Bioss Antibodies Inc., ReproCELL Inc., Jackson ImmunoResearch Laboratories Inc., Lucerna-Chem AG, LifeSpan BioSciences Inc., Creative Biogene Inc., MyBioSource Inc., Imgenex Inc., Amsbio LLC
North America was the largest region in the stem cell antibody market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in stem cell antibody report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the stem cell antibody market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The stem cell antibody market consists of sales of stem cell surface marker antibodies, fluorescent-labeled stem cell antibodies, secondary detection antibodies, stem cell differentiation marker kits, and stem cell flow cytometry antibodies. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Stem Cell Antibody Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on stem cell antibody market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for stem cell antibody ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The stem cell antibody market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:1) By Type of Antibody: Monoclonal Antibodies; Polyclonal Antibodies; Recombinant Antibodies; Bispecific Antibodies
3) By Recombinant Antibodies: Single-Chain Variable Fragment Antibodies; Fragment Antigen-Binding Antibodies; Nanobodies; Chimeric Recombinant Antibodies
3. Stem Cell Antibody Market Trends And Strategies
4. Stem Cell Antibody Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
4.1. Supply Chain Impact from Tariff War & Trade Protectionism
5. Global Stem Cell Antibody Growth Analysis And Strategic Analysis Framework
5.1. Global Stem Cell Antibody PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Stem Cell Antibody Market Growth Rate Analysis
5.4. Global Stem Cell Antibody Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Stem Cell Antibody Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Stem Cell Antibody Total Addressable Market (TAM)
6. Stem Cell Antibody Market Segmentation
6.1. Global Stem Cell Antibody Market, Segmentation By Type Of Antibody, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Monoclonal Antibodies
Polyclonal Antibodies
Recombinant Antibodies
Bispecific Antibodies
6.2. Global Stem Cell Antibody Market, Segmentation By Product Formulation, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Liquid Formulations
Lyophilized Formulations
Conjugated Antibodies
Unconjugated Antibodies
6.3. Global Stem Cell Antibody Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Research
Clinical Diagnostics
Therapeutic Use
Protein Purification
6.4. Global Stem Cell Antibody Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Academic Institutions
Pharmaceutical Companies
Biotechnology Firms
Hospitals And Diagnostic Laboratories
6.5. Global Stem Cell Antibody Market, Sub-Segmentation Of Monoclonal Antibodies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Humanized Monoclonal Antibodies
Chimeric Monoclonal Antibodies
Murine Monoclonal Antibodies
Fully Human Monoclonal Antibodies
6.6. Global Stem Cell Antibody Market, Sub-Segmentation Of Polyclonal Antibodies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Animal-Derived Polyclonal Antibodies
Recombinant Polyclonal Antibodies
Affinity-Purified Polyclonal Antibodies
Secondary Polyclonal Antibodies
6.7. Global Stem Cell Antibody Market, Sub-Segmentation Of Recombinant Antibodies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Single-Chain Variable Fragment Antibodies
Fragment Antigen-Binding Antibodies
Nanobodies
Chimeric Recombinant Antibodies
6.8. Global Stem Cell Antibody Market, Sub-Segmentation Of Bispecific Antibodies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
T-Cell Engager Bispecific Antibodies
Dual-Targeting Bispecific Antibodies
Immune Checkpoint Bispecific Antibodies
Tumor-Associated Bispecific Antibodies
7. Stem Cell Antibody Market Regional And Country Analysis
7.1. Global Stem Cell Antibody Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Stem Cell Antibody Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
